Latest news
Travere Therapeutics, Inc. Stock 12‑Month Price Target Raised to $68.36, Implies 22% Upside - TradingViewTradingView · Wed, 05 Aug 2026 21:20:21 GMTTVTX: FILSPARI's record Q2 sales and rapid FSGS launch drive strong growth and future confidence - TradingViewTradingView · Tue, 04 Aug 2026 23:17:05 GMTTVTX: FILSPARI's dual-indication launch drove record revenue and robust growth, with strong pipeline progress - TradingViewTradingView · Tue, 04 Aug 2026 22:16:25 GMTTravere Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary - TradingViewTradingView · Tue, 04 Aug 2026 21:01:40 GMTTVTX: Exclusive license for civorebrutinib adds $112.5M upfront, $1.03B milestones, and broad kidney pipeline - TradingViewTradingView · Tue, 04 Aug 2026 20:47:46 GMTTVTX: FILSPARI's rapid sales growth and pipeline expansion drive revenue, offset by higher expenses - TradingViewTradingView · Tue, 04 Aug 2026 20:11:06 GMTBRIEF-Travere Therapeutics Q2 EPS USD -0.37 - TradingViewTradingView · Tue, 04 Aug 2026 20:02:01 GMTTVTX Q2'26 Earnings: EPS estimate is (0.13) USD - TradingViewTradingView · Mon, 03 Aug 2026 11:00:47 GMT